[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 19 of about 19
1. Ono K, Arimoto H, Wada K, Takahara T, Shirotani T, Shimizu A, Sakai Y, Matsukuma S, Hatanaka K, Inohara T: Multicentric involvement of non-Hodgkin's lymphoma in the central nervous system and testis--case report. Neurol Med Chir (Tokyo); 2004 Sep;44(9):493-6
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentric involvement of non-Hodgkin's lymphoma in the central nervous system and testis--case report.
  • A 73-year-old male presented with diffuse mixed B cell lymphoma with involvement of the central nervous system (CNS) and testis manifesting as mild disorientation and aphasia.
  • Histological examination revealed diffuse mixed B cell type malignant lymphoma in the CNS and testis.
  • Pelvic computed tomography revealed enlargement of the contralateral testis and prostate.
  • Needle biopsy confirmed lymphoma.
  • Autopsy examination revealed lymphoma cell invasion of the lung, bone marrow, prostate gland, and thalamus, but without involvement of the systemic lymph nodes.
  • In a patient with an intracranial lymphoma, it is important to determine if the lesion is primary or metastatic and to plan medical treatment including systemic chemotherapy as soon as possible.
  • Improvement of the prognosis of systemic non-Hodgkin's lymphoma with CNS involvement requires the detection and effective treatment of systemic lesions as well as the control of the CNS lesions.
  • [MeSH-major] Brain Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Magnetic Resonance Imaging. Male. Orchiectomy / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15600286.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


2. Barrena-Caballo MR, Blanch-Labrador M, Giménez-Mas JA, Alberdi-Viñas J, Pascual-Piazuelo M, Zubiri-Ara L: [T-type primary lymphoma of the central nervous system in immunocompetent patients]. Rev Neurol; 2003 Jan 16-31;36(2):125-30
Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [T-type primary lymphoma of the central nervous system in immunocompetent patients].
  • [Transliterated title] Linfoma primario tipo T del sistema nervioso central en pacientes inmunocompetentes.
  • INTRODUCTION: The primary lymphoma of the central nervous system is an infrequent neoplasia, which represents 1,5% of all primary neoplasias in adult patients.
  • The non Hodgkin lymphoma of B cells being the most frequent histological type, the primary T cell lymphoma of the CNS is a rare clinical entity.
  • CASE REPORTS: In this study we present three cases of immunocompetent patients with primary lymphoma of the central nervous system of T cells seen during the 6 last years in our hospital, the diagnostic imaging by computerized tomography and magnetic resonance showed the tumorations, but the definitive diagnosis was by stereotaxic cerebral biopsy.
  • CONCLUSIONS: The lymphomas are radiosensitive to radiotherapy with survivals of approximately 26 months, the combined treatment of surgery and chemotherapy, prior to radiotherapy, may increases survival up to 48 months.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Immunocompetence. Lymphoma, T-Cell / diagnosis
  • [MeSH-minor] Adult. Biopsy. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12589598.001).
  • [ISSN] 0210-0010
  • [Journal-full-title] Revista de neurologia
  • [ISO-abbreviation] Rev Neurol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


3. Jun HJ, Kim WS, Yang JH, Yi SY, Ko YH, Lee J, Jung CW, Kang SW, Park K: Orbital infiltration as the first site of relapse of primary testicular T-cell lymphoma. Cancer Res Treat; 2007 Mar;39(1):40-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital infiltration as the first site of relapse of primary testicular T-cell lymphoma.
  • The pathologic diagnosis of the radical orchiectomy specimen was peripheral T-cell lymphoma, unspecified (PTCL-u).
  • According to the Ann Arbor staging system, his initial stage was III because of the right nasopharyngeal involvement.
  • After first-line chemotherapy with four courses of the CHOP regimen and this was followed by involved-field radiotherapy, he achieved complete remission.
  • Although the patient received intensive chemotherapy with autologous hematopoietic stem cell transplantation, he ultimately died of leptomeningeal seeding.
  • Because both the central nervous system (CNS) and the orbit are sanctuary sites for chemotherapy, orbital infiltration of lymphoma should prompt physicians to evaluate involvement of the CNS and to consider performing prophylactic intrathecal chemotherapy as a treatment option.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmology. 1999 Nov;106(11):2109-20 [10571346.001]
  • [Cites] Eur J Cancer. 1994;30A(12):1760-4 [7880601.001]
  • [Cites] Am J Surg Pathol. 1994 Apr;18(4):376-90 [8141430.001]
  • [Cites] Histopathology. 1989 Aug;15(2):147-56 [2777217.001]
  • [Cites] Br J Urol. 1984 Oct;56(5):525-30 [6398719.001]
  • [Cites] Arch Ophthalmol. 1984 Mar;102(3):399-402 [6608342.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):154-61 [10618618.001]
  • (PMID = 19746228.001).
  • [ISSN] 1598-2998
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2739356
  • [Keywords] NOTNLM ; Eye neoplasm / Non-Hodgkin's lymphoma / T cell lymphoma / Testes
  •  go-up   go-down


Advertisement
4. Harbell JW, Dunn TB, Fauda M, John DG, Goldenberg AS, Teperman LW: Transmission of anaplastic large cell lymphoma via organ donation after cardiac death. Am J Transplant; 2008 Jan;8(1):238-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transmission of anaplastic large cell lymphoma via organ donation after cardiac death.
  • We present a case of anaplastic T-cell lymphoma transmitted to four recipients of solid organ transplants from a DCD donor suspected of having bacterial meningitis.
  • On brain biopsy, the donor was found to have anaplastic central nervous system T-cell lymphoma, and the recipient of the donor's pancreas, liver and kidneys were found to have involvement of T-cell lymphoma.
  • The transplanted kidneys and pancreas were excised from the respective recipients, and the kidney and pancreas recipients responded well to chemotherapy.
  • The liver recipient underwent three cycles of chemotherapy, but later died due to complications of severe tumor burden.
  • In cases of lymphoma transmission, excision of the graft may be the only chance at long-term survival.
  • [MeSH-major] Death. Lymphoma, Large-Cell, Anaplastic / diagnosis. Lymphoma, Large-Cell, Anaplastic / etiology. Organ Transplantation / adverse effects. Tissue Donors


5. Corns R, Crocker M, Kumar A, Salisbury J, Tolias C, Sadler G, Hill M: Low grade cerebellar T-cell lymphoma: a novel response to treatment; a case report. Acta Neurochir (Wien); 2010 Jun;152(6):1075-7
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low grade cerebellar T-cell lymphoma: a novel response to treatment; a case report.
  • Low-grade primary T-cell lymphoma of the central nervous system is extremely rare.
  • Biopsy of this lesion revealed features of non-Hodgkin's lymphoma with histochemical analysis confirming T-cell phenotype and a Ki67 proliferation index of only 1%.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Cerebellar Neoplasms / drug therapy. Cerebellar Neoplasms / radiotherapy. Cranial Irradiation. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / radiotherapy. Methotrexate / therapeutic use
  • [MeSH-minor] Adult. Antineoplastic Agents, Hormonal / therapeutic use. Biomarkers, Tumor / analysis. Biopsy. Cerebellum / pathology. Combined Modality Therapy. Dexamethasone / therapeutic use. Dose-Response Relationship, Drug. Female. Humans. Infusions, Intravenous. Ki-67 Antigen / analysis. Magnetic Resonance Imaging. Neurologic Examination. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19936608.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 7S5I7G3JQL / Dexamethasone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


6. Hansen PB, Jensen MK: [Primary non-Hodgkin's lymphomas of the central nervous system. Still more questions than answers in the treatment?]. Ugeskr Laeger; 2007 Jun 4;169(23):2187-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary non-Hodgkin's lymphomas of the central nervous system. Still more questions than answers in the treatment?].
  • [Transliterated title] Primaere non-Hodgkin-lymfomer i centralnervesystemet. Stadig flere spørgsmål end svar i behandlingen?
  • The optimal treatment of primary non-Hodgkin"s lymphomas of the central nervous system is still under discussion.
  • Systemic treatment is compromised by the blood-brain barrier which is impermeable to several cytostatic agents.
  • For several years, the standard treatment has been methotrexate-based chemotherapy followed by CNS-radiotherapy.
  • However, this combination therapy may be complicated by later neurotoxicity.
  • Intensive chemotherapy followed by autologous stem-cell transplantation is a new promising treatment approach without increased CNS-toxicity.
  • [MeSH-major] Brain Neoplasms / therapy. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / radiotherapy. Lymphoma, B-Cell / therapy. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / radiotherapy. Lymphoma, T-Cell / therapy. Stem Cell Transplantation. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17592682.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 25
  •  go-up   go-down


7. Guo HY, Zhao XM, Cao JN, Hu XC, Yin JL, Hong XN, Li J: [Prognosis of primary non-Hodgkin's lymphoma of the breast]. Zhonghua Zhong Liu Za Zhi; 2008 Mar;30(3):200-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognosis of primary non-Hodgkin's lymphoma of the breast].
  • OBJECTIVE: To analyze the clinical characteristics and prognosis of primary non-Hodgkin's lymphoma of the breast (PNHLB).
  • METHODS: The characteristics, treatment methods and outcomes of 45 patients with PNHLB were retrospectively analyzed.
  • Chemotherapy including CHOP and CHOP-like regimens was administered in 43 patients, and monoclonal antibody therapy in 6 patients.
  • Furthermore, 19 patients underwent radiotherapy after chemotherapy.
  • RESULTS: Of these 45 patients, 37 patients had diffuse large B cell lymphoma (DLBCL), patients with T cell or mucosa-associated lymphoid tissue (MALT) lymphoma were 4, respectively.
  • Overall response rate of first-line chemotherapy was 90.7%.
  • Central nervous system involvement (RR = 1.107, P = 0.005) was a negative independent prognostic factor for PFS.
  • Most pathologic type was DLBCL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal / therapeutic use. Breast Neoplasms, Male / drug therapy. Breast Neoplasms, Male / pathology. Breast Neoplasms, Male / radiotherapy. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, B-Cell, Marginal Zone / radiotherapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / radiotherapy. Male. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Prognosis. Proportional Hazards Models. Radiotherapy, Adjuvant. Remission Induction. Retrospective Studies. Survival Rate. Vincristine / therapeutic use. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18756936.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


8. Nagasaki A, Miyagi T, Nakazato T, Taira N, Ohshima K, Kikuchi M, Takasu N, Masauda M: Very late central nervous system relapse in a patient with B cell lymphoblastic lymphoma. Acta Haematol; 2004;112(4):212-6
Genetic Alliance. consumer health - Lymphoblastic lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Very late central nervous system relapse in a patient with B cell lymphoblastic lymphoma.
  • Very late relapse of lymphoblastic lymphoma (LBL) is very rare.
  • We report a case of a patient who developed central nervous system (CNS) relapse of LBL 16 years after the onset of the primary disease.
  • Examination of a biopsy of the skin tumor showed typical features of non-Hodgkin's lymphoma (diffuse medium-sized cell type).
  • She received multiagent chemotherapy and went into remission.
  • Revised immunohistochemistry of the primary specimens of skin tumor obtained 16 years earlier revealed a phenotype similar to that of the CNS disease.
  • Thus, the original diagnosis of diffuse medium-sized lymphoma was revised to B cell LBL.
  • An isolated CNS relapse of LBL was apparent in the present case.
  • After salvage chemotherapy, the patient underwent high-dose chemotherapy with autologous peripheral blood stem cell support and subsequent craniospinal irradiation.
  • [MeSH-major] Central Nervous System Neoplasms / secondary. Lymphoma, B-Cell / pathology
  • [MeSH-minor] Cell Proliferation. Child. Combined Modality Therapy. Female. Humans. Immunophenotyping. Magnetic Resonance Imaging. Neoplasm Invasiveness. Peripheral Blood Stem Cell Transplantation. Recurrence. Salvage Therapy. Skin Neoplasms / pathology. Skin Neoplasms / therapy. Transplantation, Autologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2004 S. Karger AG, Basel.
  • (PMID = 15564734.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


9. Gerstner E, Batchelor T: Primary CNS lymphoma. Expert Rev Anticancer Ther; 2007 May;7(5):689-700
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary CNS lymphoma.
  • Primary CNS lymphoma, an uncommon form of extranodal non-Hodgkin's lymphoma, has increased in incidence and occurs in both immunocompromised and immunocompetent hosts.
  • Primary CNS lymphoma in immunocompetent patients is associated with unique diagnostic, prognostic and therapeutic issues and the management of this malignancy is different from other forms of extranodal non-Hodgkin's lymphoma.
  • Since primary CNS lymphoma may involve the brain, cerebrospinal fluid and eyes, diagnostic evaluation should include assessment of all of these regions as well as screening for the possibility of occult systemic disease.
  • Resection provides no therapeutic benefit and should be reserved for the rare patient with neurological deterioration due to brain herniation.
  • Whole-brain radiation therapy alone is insufficient for durable tumor control and is associated with a high risk of neurotoxicity in patients over 60 years of age.
  • Chemotherapy and whole-brain radiation therapy together improve tumor response rates and survival compared with whole-brain radiation therapy alone.
  • Methotrexate-based multiagent chemotherapy without whole-brain radiation therapy is associated with similar tumor response rates and survival compared with regimens that include whole-brain radiation therapy, although controlled trials have not been performed.
  • The risk of neurotoxicity is lower in patients treated with chemotherapy alone.
  • The incidence of HIV-related primary CNS lymphoma has decreased in the era of highly active antiretroviral therapy.
  • Patients with HIV-associated primary CNS lymphoma have a worse prognosis but may respond to highly active antiretroviral therapy, whole-brain radiation therapy or therapies directed against the Epstein-Barr virus.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / radiotherapy. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Antiretroviral Therapy, Highly Active. Combined Modality Therapy. HIV Infections / complications. HIV Infections / drug therapy. Humans. Injections, Spinal. Methotrexate / administration & dosage. Prognosis. Radiotherapy / adverse effects. Stem Cell Transplantation

  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Pneumocystosis and HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17492932.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 71
  •  go-up   go-down


10. Lasota J, Nordling S, Miettinen M: Testicular diffuse large cell lymphoma with tubule preservation--molecular genetic evidence of transformation from previous follicular lymphoma. Virchows Arch; 2000 Mar;436(3):276-83
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular diffuse large cell lymphoma with tubule preservation--molecular genetic evidence of transformation from previous follicular lymphoma.
  • Testicular lymphomas usually occur in older men and are mostly diffuse large B-cell lymphomas (DLBL).
  • They may be primary manifestation of lymphoma or represent a relapse of a previous non-Hodgkin's lymphoma.
  • This report details a testicular large cell lymphoma, which was proven to be large cell transformation of a low-grade follicular lymphoma biopsied 8 years earlier.
  • Initially, a 38-year old man was diagnosed with cervical lymphadenopathy, and biopsy was interpreted as reactive follicular hyperplasia; no treatment was given, and the lymphadenopathy resolved spontaneously.
  • The patient died 7 months later with evidence for intra-abdominal and central nervous system lymphoma after a brief but temporary response to M-BACOD chemotherapy.
  • Orchiectomy specimen and gastroscopic biopsy showed diffuse large B-cell lymphoma (CD20+), which infiltrated between well-preserved tubules in the testis.
  • Histological comparison with 20 testicular lymphomas without previous lymphoma showed tubule infiltration in all cases, suggesting that the tubule-preserving infiltration pattern could be a histological marker for secondary lymphoma involvement in testis.
  • On re-examination, the lymph node 8 years prior was verified as follicular, predominantly small, cleaved cell lymphoma with bcl2-positive follicles.
  • The earlier follicular lymphoma and the subsequent diffuse large cell lymphoma were analyzed using polymerase chain reaction and showed identical sequences of the t(14;18) translocation and immunoglobulin heavy chain gene rearrangement.
  • Analysis of the VH-gene sequences from the follicular lymphoma revealed sequence heterogeneity consistent with ongoing mutation.
  • However, the transformed diffuse large cell lymphoma had no intraclonal variation, with the sequence matching with one of the subclones from the low-grade follicular lymphoma.
  • These results confirm that the large cell transformation of follicular lymphoma occurs in a single follicular lymphoma cell.
  • This case also indicates that the selection of the transformed clone can be part of the natural history of disease and can occur without exposure to chemotherapy.
  • [MeSH-major] Cell Transformation, Neoplastic. Genes, Immunoglobulin. Lymphoma, Follicular / genetics. Lymphoma, Follicular / pathology. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / pathology. Testicular Neoplasms / genetics. Testicular Neoplasms / pathology
  • [MeSH-minor] Base Sequence. Cell Differentiation. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 18. Gene Rearrangement, B-Lymphocyte. Humans. Immunoglobulin Heavy Chains / genetics. Male. Molecular Sequence Data. Polymerase Chain Reaction. Translocation, Genetic

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10782887.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


11. Guinto G, Félix I, Aréchiga N, Arteaga V, Kovacs K: Primary central nervous system lymphomas in immunocompetent patients. Histol Histopathol; 2004 07;19(3):963-72
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system lymphomas in immunocompetent patients.
  • Primary Central nervous system lymphoma is a rare non-Hodgkin's tumor of the brain that has been traditionally found in patients with immunodeficiency syndromes.
  • Immunohistochemistry has demonstrated that most of the tumor cells are B-lymphocytes and the electron microscopic findings do not differ from those reported in systemic non-Hodgkin's lymphomas.
  • The treatment is based on a combination of chemotherapy followed by radiotherapy, but the mortality rate is still high.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Lymphoma, T-Cell / diagnosis
  • [MeSH-minor] Antimetabolites, Antineoplastic / therapeutic use. Combined Modality Therapy. Humans. Magnetic Resonance Imaging. Methotrexate / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15168358.001).
  • [ISSN] 0213-3911
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 63
  •  go-up   go-down


12. Butrón Valdez K, Ramírez Galves M, Germes Piña F, Ramos Martínez E, Zamora Perea A: [Systemic lymphoma cells with T precursor condition of extreme female genital tract. A case report and literature review]. Ginecol Obstet Mex; 2009 Jun;77(6):291-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Systemic lymphoma cells with T precursor condition of extreme female genital tract. A case report and literature review].
  • Primary female genital tract non Hodgkin's lymphoma is a rare presentation for a common disease in the childhood, and its classification as primary extranodal lymphoma is still controversial.
  • There are a few cases reported as a primary precursor B-cell lymphoblastic lymphoma of the female genital tract, but there is not any case reported as primary precursor T-cell lymphoblastic lymphoma of the ovary in childhood.
  • The chemotherapy regimen comprised of CHOP (Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone) and methotrexate, 3 months later presents left facial hemiparesia follow by right facial hemiparesia, 7 months later presents more Central Nervous System (CNS) complications and apparently was complicated with acute lymphocitic leukemia and after 16 months from the diagnosis, following by a torpid evolution, the pacient finally died.
  • [MeSH-major] Genital Neoplasms, Female. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19681371.001).
  • [ISSN] 0300-9041
  • [Journal-full-title] Ginecología y obstetricia de México
  • [ISO-abbreviation] Ginecol Obstet Mex
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Mexico
  • [Number-of-references] 19
  •  go-up   go-down


13. Corti M, Villafañe Fioti MF, Lewi D, Schtirbu R, Narbaitz M, de Dios Soler M: [Non-Hodgkin's lymphomas of the digestive tract and anexal glands in AIDS patients]. Acta Gastroenterol Latinoam; 2006 Dec;36(4):190-6
HIV InSite. treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-Hodgkin's lymphomas of the digestive tract and anexal glands in AIDS patients].
  • BACKGROUND: Non-Hodgkin's lymphoma (NHL) is the second most common neoplasm among patients with AIDS.
  • All patients were staged by computed tomography scanning and bone marrow examination, in addition to the endoscopic evaluation.
  • RESULTS: All patients were males; 4 were heterosexual, 2 homosexual, and 1 were a hemophilic and an intravenous drug abuser.
  • The median age was 42 years and the median CD4 T cell count was 87 cells/uL at the time of the diagnosis of neoplasm.
  • No patient was receiving highly active antiretroviral therapy (HAART) at lymphoma diagnosis.
  • The global incidence of AIDS-associated lymphomas (central nervous system lymphomas, non-Hodgkin lymphomas and Hodgkin lymphoma) during the time of study was 2,9% (54 cases); 17 patients (32%) had diagnosis of systemic NHL; 10 (58,8%) of them were extranodal at the onset of clinical symptoms and 8 (80%) involvement the digestive tract and anexal glands (parotid gland, cavum, esophagus, stomach, duodenum, the right colon in 2 patients and the liver), as primary NHL of high grade and "B" phenotype.
  • All patients presented "B" symptoms at the time of diagnosis.
  • Primary duodenal lymphoma was the only Burkitt lymphoma of this serie and we detected the Epstein-Barr virus genome in the biopsy smears of this tumor and in the hepatic lymphoma.
  • Four patients were treated with systemic chemotherapy with granulocitic growth factor support plus highly active antiretroviral therapy (HAART); 2 of them (cavum and one of the colon) had a prolonged survival with immune reconstitution during 5 and 6 years, respectively, after the diagnosis.
  • The median survival of the patients, which received HAART plus chemotherapy, was 33 months.
  • Early diagnosis followed by chemotherapy plus HAART are necessary to improve the prognosis and the survival of these patients.
  • [MeSH-major] Gastrointestinal Neoplasms / diagnosis. Liver Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Parotid Neoplasms / diagnosis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17225446.001).
  • [ISSN] 0300-9033
  • [Journal-full-title] Acta gastroenterologica Latinoamericana
  • [ISO-abbreviation] Acta Gastroenterol. Latinoam.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Argentina
  •  go-up   go-down


14. Jahnke K, Thiel E, Schilling A, Herrlinger U, Weller M, Coupland SE, Krümpelmann U, Stein H, Korfel A: Low-grade primary central nervous system lymphoma in immunocompetent patients. Br J Haematol; 2005 Mar;128(5):616-24
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade primary central nervous system lymphoma in immunocompetent patients.
  • Primary central nervous system lymphomas (PCNSL) are usually diffuse large B-cell non-Hodgkin's lymphomas (NHL).
  • Seven patients had B-cell and three had T-cell lymphoma.
  • Three patients underwent complete tumour resection, combined with chemotherapy in one patient and with chemotherapy plus local radiotherapy in another.
  • Four patients received chemotherapy and three received chemotherapy plus whole-brain irradiation, resulting in four complete remissions, two no-change situations and one progressive disease.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Lymphoma / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Lymphoma, B-Cell / mortality. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / therapy. Lymphoma, T-Cell / mortality. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / therapy. Magnetic Resonance Imaging. Male. Middle Aged. Survival Rate

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15725082.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


15. Stark AM, Tiemann M, Dörner L, Melnikowa E, Mehdorn HM, Blömer U: Primary peripheral T-cell lymphoma of the central nervous system. Zentralbl Neurochir; 2004 Nov;65(4):191-4
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary peripheral T-cell lymphoma of the central nervous system.
  • Open brain biopsy revealed primary central nervous system lymphoma of the extraordinary rare so-called "peripheral" T-cell type.
  • The further course was fatal; the patient died 10 weeks after the onset of symptoms from tumor progression before planned chemotherapy could be started.
  • CONCLUSION: If primary central nervous system lymphoma (PCNSL) is suspected, brain biopsy -- either open biopsy or stereotactic biopsy -- should be performed straight away to enable a rapid start of chemotherapy and/or radiotherapy.
  • Peripheral T-cell lymphoma was highly aggressive in this case leading to the patient's death within several weeks.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Lymphoma, T-Cell / pathology

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15551184.001).
  • [ISSN] 0044-4251
  • [Journal-full-title] Zentralblatt für Neurochirurgie
  • [ISO-abbreviation] Zentralbl. Neurochir.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Linassier C, Desablens B, Lefrancq T, Le Prise PY, Harousseau JL, Jacob C, Gandhour C, Haillot O, Lucas V, Leloup R, Escoffre M, Colombat P, Tabuteau S, GOELAMS Study Group: Stage I-IIE primary non-Hodgkin's lymphoma of the testis: results of a prospective trial by the GOELAMS Study Group. Clin Lymphoma; 2002 Dec;3(3):167-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage I-IIE primary non-Hodgkin's lymphoma of the testis: results of a prospective trial by the GOELAMS Study Group.
  • Sixteen patients with aggressive primary testicular involvement were analyzed separately from a prospective multicenter series of 494 patients with stage I/II aggressive nonlymphoblastic lymphoma.
  • The treatment strategy included 3 cycles of anthracycline-based chemotherapy followed by regional radiation therapy on inguinal, iliac, and para-aortic lymph nodes and central nervous system (CNS) prophylaxis by intrathecal chemotherapy and brain irradiation.
  • Chemotherapy was stratified by age group.
  • Patients aged 18-60 years received the Groupe Ouest Est d'Etude des Leucemies Aigues et Maladies du Sang (GOELAMS) 02 protocol: 3 monthly cycles of VCAP (vindesine 3 mg/m2 day 1, doxorubicin 80 mg/m2 day 2, cyclophosphamide 1500 mg/m2 day 2, and prednisone 80 mg/m2 days 1-5).
  • The histological subtypes were diffuse large-cell lymphoma in all cases.
  • One patient died from septic shock during the last course of chemotherapy.
  • Relapse in the CNS occurred in only 1 patient and in the contralateral testis in 1 patient.
  • This is the first report of a prospective study in which treatment of testicular non-Hodgkin's lymphoma was precisely defined at diagnosis.
  • Compared to other series, a combination of orchiectomy with 3 cycles of CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone)-derived chemotherapy, regional radiation therapy, and CNS prophylaxis seems to improve prognosis.
  • The improvement in prognosis seemed to be due in part to irradiation, including the pelvic and lomboaortic lymphatic areas, and in part to CNS prophylaxis.
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adult. Age Factors. Aged. Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Brain / radiation effects. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Epirubicin / therapeutic use. Humans. Lymph Nodes / pathology. Male. Middle Aged. Prednisone / therapeutic use. Prognosis. Prospective Studies. Recurrence. Time Factors. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Lymphoma. 2002 Dec;3(3):173-4 [12521395.001]
  • (PMID = 12521394.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin; 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CEV protocol; CHOP protocol
  •  go-up   go-down


17. Laskin JJ, Savage KJ, Voss N, Gascoyne RD, Connors JM: Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxis. Leuk Lymphoma; 2005 Dec;46(12):1721-7
Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxis.
  • Non-Hodgkin's lymphoma of the paranasal sinus is an uncommon presentation of extranodal lymphoma.
  • Its natural history, treatment and prognosis have been infrequently characterized in the medical literature; however, a tendency to involve the central nervous system (CNS) has been noted.
  • In British Columbia (population 4 million), a central database for lymphomas has allowed us to accurately track cases of paranasal sinus lymphoma diagnosed since 1980.
  • A retrospective review was performed on the 44 patients who presented with primary paranasal sinus lymphoma (stage I or II) between 1980 and 1999.
  • Complete diagnostic and follow-up data including stage, treatment, response rates, sites of relapse and survival data were available for all patients.
  • The types of lymphoma found were: diffuse large B cell (including immunoblastic), n = 37 (84%); T/NK nasal type, n = 3 (8%); peripheral T cell, not otherwise classified, n = 2 (4%); and others, n = 2 (4%).
  • Beginning in May 1985, intrathecal chemotherapy was added to our standard treatment plan of multi-agent chemotherapy and local irradiation.
  • Before 1985, 2 of 5 patients developed leptomeningeal metastasis.
  • Following the institution of intrathecal chemotherapy, only 8% (3 of 39) of patients have developed CNS disease.
  • Primary paranasal sinus lymphoma is an uncommon presentation of lymphoma that carries the potential risk of spreading to the leptomeninges.
  • Treatment with combined modality chemotherapy and irradiation can cure many patients and the addition of intrathecal chemotherapy may reduce the risk of CNS relapse.
  • [MeSH-major] Chemoprevention. Lymphoma, Non-Hodgkin / physiopathology. Paranasal Sinus Neoplasms / physiopathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / prevention & control. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Analysis. Survivors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16263574.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


18. Hoffman PM, McKelvie P, Hall AJ, Stawell RJ, Santamaria JD: Intraocular lymphoma: a series of 14 patients with clinicopathological features and treatment outcomes. Eye (Lond); 2003 May;17(4):513-21
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraocular lymphoma: a series of 14 patients with clinicopathological features and treatment outcomes.
  • AIMS: To assess the clinical features, pathology, mortality (systemic outcome) and ocular complications (visual outcome) of a cohort of patients treated for intraocular lymphoma.
  • METHODS: Retrospective case analysis of medical records and review of pathology of a consecutive series of patients presenting with intraocular lymphoma in Melbourne over 11 years between 1990 and 2000.
  • In all, 10 patients had B-cell lymphoma, three patients T-cell lymphoma and one null-cell.
  • Four patients had prior systemic lymphoma.
  • Eight patients had primary central nervous system non-Hodgkin's lymphoma (PCNSL).
  • Treatment included combined radiation to the eye and chemotherapy in 10 patients.
  • A total of 11 patients died of lymphoma (79%).
  • Although currently disease free, one of these has a poor visual outcome with acuity less than 6/60 secondary to ocular complications of treatment.
  • CONCLUSIONS: Our study had 29% with prior systemic lymphoma, 57% associated with PCNSL and 14% with intraocular disease only.
  • [MeSH-major] Eye Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Prognosis. Radiation Injuries / etiology. Radiotherapy / adverse effects. Recurrence. Retrospective Studies. Survival Analysis. Treatment Outcome. Vision Disorders / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12802353.001).
  • [ISSN] 0950-222X
  • [Journal-full-title] Eye (London, England)
  • [ISO-abbreviation] Eye (Lond)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


19. al-Ghamdi H, Sabbah R, Martin J, Patay Z: Primary T-cell lymphoma of the brain in children: a case report and literature review. Pediatr Hematol Oncol; 2000 Jun;17(4):341-3
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary T-cell lymphoma of the brain in children: a case report and literature review.
  • Described here are the clinical features and results of treatment in a 10-year-old Saudi Arabian girl with primary T-cell lymphoma of the central nervous system.
  • The diagnosis was established by tissue biopsy obtained from the cerebellum.
  • Therapy included cranio-spinal irradiation and combination chemotherapy of a systemic high dose of methotrexate, cytosine, arabinoside, and L-asparaginase.
  • Remission was obtained easily but was interrupted by a local intracranial relapse 57 months after diagnosis (37 months after cessation of therapy; at present the patient is still alive and receiving palliative treatment).
  • [MeSH-major] Brain Neoplasms. Lymphoma, T-Cell
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Arabinose / therapeutic use. Asparaginase / therapeutic use. Child. Combined Modality Therapy. Cytosine / therapeutic use. Female. Humans. Methotrexate / therapeutic use. Recurrence. Remission Induction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10845234.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 8J337D1HZY / Cytosine; B40ROO395Z / Arabinose; EC 3.5.1.1 / Asparaginase; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down






Advertisement